account_balance
Investment manager · 13F filer · SEC CIK 1844645
Pivotal bioVenture Partners Investment Advisor LLC
Reported value$308Mas of Jun 30, 2026
Positions13 1 new, 1 sold out
Top 10 weight95.1%PCVX alone is 27%
FiledAug 1344 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
PCVXVaxcyte Inc
26.9%Added +4%
ARQTArcutis Biotherapeutics Inc
10.8%Trimmed −7%
TRVITrevi Therapeutics Inc
10.6%Added +12%
AVLNAvalyn Pharmaceuticals Inc
10.3%New
EVMNEvommune Inc
8.3%
MPLTMaplight Therapeutics Inc
7.1%
OCSOculis Holding AG
6.8%Trimmed −10%
BIOABioage Labs Inc
5.2%
IMNMImmunome Inc
5.0%
ZBIOZenas Biopharma Inc
4.0%Trimmed −17%
AVTXAvalo Therapeutics Inc
2.6%Added +47%
RLYB1.6%PCVXVaxcyte Inc
26.9%Added +4%
ARQT10.8%TRVI10.6%AVLN10.3%EVMN8.3%MPLT7.1%OCS6.8%BIOA5.2%IMNM5.0%ZBIO4.0%AVTX2.6%RLYBBoxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
PCVX Vaxcyte Inc 26.9% Added +4%ARQT Arcutis Biotherapeutics Inc 10.8% Trimmed −7%TRVI Trevi Therapeutics Inc 10.6% Added +12%AVLN Avalyn Pharmaceuticals Inc 10.3% NewEVMN Evommune Inc 8.3% HeldMPLT Maplight Therapeutics Inc 7.1% HeldOCS Oculis Holding AG 6.8% Trimmed −10%BIOA Bioage Labs Inc 5.2% HeldIMNM Immunome Inc 5.0% HeldZBIO Zenas Biopharma Inc 4.0% Trimmed −17%AVTX Avalo Therapeutics Inc 2.6% Added +47%RLYB Rallybio Corp 1.6% Held
What changed